ZA200711020B - Erythropoietin receptor peptide formulations and uses - Google Patents

Erythropoietin receptor peptide formulations and uses

Info

Publication number
ZA200711020B
ZA200711020B ZA200711020A ZA200711020A ZA200711020B ZA 200711020 B ZA200711020 B ZA 200711020B ZA 200711020 A ZA200711020 A ZA 200711020A ZA 200711020 A ZA200711020 A ZA 200711020A ZA 200711020 B ZA200711020 B ZA 200711020B
Authority
ZA
South Africa
Prior art keywords
erythropoietin receptor
receptor peptide
peptide formulations
formulations
erythropoietin
Prior art date
Application number
ZA200711020A
Other languages
English (en)
Inventor
Duliege Anne-Marie
Stead Richard
Leuther Kerstin
Woodburn Kathryn
Naso Robert Barnett
Original Assignee
Affymax Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affymax Inc filed Critical Affymax Inc
Publication of ZA200711020B publication Critical patent/ZA200711020B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A61K47/665—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells the pre-targeting system, clearing therapy or rescue therapy involving biotin-(strept) avidin systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nanotechnology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Endocrinology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
ZA200711020A 2005-06-03 2007-12-19 Erythropoietin receptor peptide formulations and uses ZA200711020B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US68765505P 2005-06-03 2005-06-03

Publications (1)

Publication Number Publication Date
ZA200711020B true ZA200711020B (en) 2008-12-31

Family

ID=37499033

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200711020A ZA200711020B (en) 2005-06-03 2007-12-19 Erythropoietin receptor peptide formulations and uses

Country Status (20)

Country Link
US (2) US7550433B2 (enExample)
EP (1) EP1917023A4 (enExample)
JP (2) JP2008542399A (enExample)
KR (2) KR20120119921A (enExample)
CN (1) CN101553242A (enExample)
AU (1) AU2006255081B2 (enExample)
BR (1) BRPI0613233A2 (enExample)
CA (1) CA2609401A1 (enExample)
CR (1) CR9570A (enExample)
EA (1) EA014528B1 (enExample)
GE (1) GEP20135981B (enExample)
IL (1) IL187354A0 (enExample)
MA (1) MA29557B1 (enExample)
MX (1) MX2007015303A (enExample)
NO (1) NO20076634L (enExample)
NZ (1) NZ563433A (enExample)
SG (1) SG162747A1 (enExample)
UA (1) UA92497C2 (enExample)
WO (1) WO2006133144A2 (enExample)
ZA (1) ZA200711020B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8324159B2 (en) * 2005-06-03 2012-12-04 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US7550433B2 (en) * 2005-06-03 2009-06-23 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US7919461B2 (en) * 2005-06-03 2011-04-05 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
EP2076290B1 (en) 2006-10-27 2016-12-14 Sunnybrook Health Sciences Center Multimeric tie 2 agonists and uses thereof in stimulating angiogenesis
EP2118127A4 (en) * 2007-01-31 2010-12-01 Affymax Inc NICKET-BASED LINKER FOR BONDING MODIFYING GROUPS OF POLYPEPTIDES AND OTHER MACROMOLECULES
JP2010536857A (ja) * 2007-08-22 2010-12-02 武田薬品工業株式会社 エリスロポエチン受容体ペプチドの製剤及び使用
JP2009191056A (ja) * 2008-02-15 2009-08-27 Affymax Inc 合成ペプチドをベースとするｅｐｏレセプターアゴニストを用いた抗エリスロポエチン抗体に媒介された障害の治療
CN103044539B (zh) * 2010-04-09 2014-10-22 苏州元基生物技术有限公司 重组促红细胞生成素及制备方法
CN102838677B (zh) * 2010-04-09 2014-10-22 苏州元基生物技术有限公司 重组促红细胞生成素及制备方法
CN102210872A (zh) * 2011-05-30 2011-10-12 深圳翰宇药业股份有限公司 一种聚乙二醇修饰肽药物制剂及其制备方法
CN103450348B (zh) * 2012-05-29 2016-03-30 中国人民解放军军事医学科学院毒物药物研究所 一种促红细胞生成素模拟肽、其制备方法和用途
CN104231067B (zh) * 2013-06-07 2017-08-11 中国人民解放军军事医学科学院毒物药物研究所 促红细胞生成素模拟肽化学二聚体及其用途
CN105837681B (zh) * 2015-01-13 2019-04-19 天津药物研究院 一种促红细胞生成素模拟肽衍生物、其制备方法和用途
CN106279398B (zh) * 2015-06-26 2019-06-28 天津药物研究院有限公司 一种促红细胞生成素模拟肽及其制备方法和应用
CN106317217B (zh) * 2015-06-26 2019-06-28 天津药物研究院有限公司 一种促红细胞生成素模拟肽及其制备方法和应用
CN105085654B (zh) * 2015-08-26 2019-01-08 天津药物研究院有限公司 一种促红细胞生成素模拟肽及其制备方法和应用
CN105153293B (zh) * 2015-08-26 2019-01-08 天津药物研究院有限公司 一种促红细胞生成素模拟肽及其二聚体、以及制备方法和应用
CN105085653B (zh) * 2015-08-26 2019-01-08 天津药物研究院有限公司 一种促红细胞生成素模拟肽及其制备方法和应用
CN105418754A (zh) * 2015-09-30 2016-03-23 天津药物研究院有限公司 羟乙基淀粉修饰的促红细胞生成素模拟肽及其制备和应用
CN106608913B (zh) * 2015-10-22 2020-05-05 天津药物研究院有限公司 一种1，2，3-丙三酸偶联的epo拟肽衍生物及其制备方法和应用
CN106608912B (zh) * 2015-10-22 2019-09-20 天津药物研究院有限公司 一种脂肪二羧酸偶联的epo模拟肽衍生物及其制备方法和应用
CN106608911B (zh) * 2015-10-22 2020-01-07 天津药物研究院有限公司 一种二硫键修饰的epo拟肽衍生物及其制备方法和应用
CN105367629B (zh) * 2015-11-09 2019-01-08 天津药物研究院有限公司 一种促红细胞生成素模拟肽以及其制备方法和用途
CN116077741A (zh) * 2022-08-24 2023-05-09 深圳先进技术研究院 一种可固定细胞并在体内实现细胞增殖和释放的微米级3d细胞生物支架及其应用

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4703008A (en) 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
KR850004274A (ko) * 1983-12-13 1985-07-11 원본미기재 에리트로포이에틴의 제조방법
NZ210501A (en) * 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
US4677195A (en) * 1985-01-11 1987-06-30 Genetics Institute, Inc. Method for the purification of erythropoietin and erythropoietin compositions
US4925673A (en) 1986-08-18 1990-05-15 Clinical Technologies Associates, Inc. Delivery systems for pharmacological agents encapsulated with proteinoids
US5080891A (en) * 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5006333A (en) * 1987-08-03 1991-04-09 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
WO1990008822A1 (en) * 1989-02-03 1990-08-09 Genetics Institute, Inc. Erythropoietin receptor
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
DE69026306T2 (de) 1989-05-27 1996-10-17 Seikagaku Kogyo Co Ltd Verfahren für die Herstellung von Polyethylenglykolderivate und modifizierte Proteine.
US5424186A (en) 1989-06-07 1995-06-13 Affymax Technologies N.V. Very large scale immobilized polymer synthesis
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5723286A (en) 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
US5292654A (en) * 1990-12-13 1994-03-08 Whitehead Institute For Biomedical Research Mutant EPO receptor and uses therefor
JP3507486B2 (ja) 1991-03-15 2004-03-15 アムジエン・インコーポレーテツド 顆粒球コロニー刺激因子の肺内投与
ES2199935T3 (es) 1991-03-15 2004-03-01 Amgen Inc. Pegilacion de polipeptidos.
CA2101918A1 (en) 1991-03-18 1992-09-19 Samuel Zalipsky Hydrazine containing conjugates of polypeptides and glycopolypeptides with polymers
CA2118806A1 (en) 1991-09-18 1993-04-01 William J. Dower Method of synthesizing diverse collections of oligomers
US6153407A (en) * 1992-07-28 2000-11-28 Beth Israel Deaconess Medical Center Erythropoietin DNA having modified 5' and 3' sequences and its use to prepare EPO therapeutics
US5614184A (en) * 1992-07-28 1997-03-25 New England Deaconess Hospital Recombinant human erythropoietin mutants and therapeutic methods employing them
US5888511A (en) * 1993-02-26 1999-03-30 Advanced Biotherapy Concepts, Inc. Treatment of autoimmune diseases, including AIDS
US5919455A (en) * 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5773569A (en) * 1993-11-19 1998-06-30 Affymax Technologies N.V. Compounds and peptides that bind to the erythropoietin receptor
US5830851A (en) * 1993-11-19 1998-11-03 Affymax Technologies N.V. Methods of administering peptides that bind to the erythropoietin receptor
US5580853A (en) * 1994-03-22 1996-12-03 New England Deaconess Hospital Modified polypeptides with increased biological activity
US5747446A (en) * 1994-03-22 1998-05-05 Beth Israel Deaconess Medical Center Modified polypeptides with increased biological activity
US5919758A (en) * 1994-03-22 1999-07-06 Beth Israel Deaconess Medical Center Modified polypeptides with altered biological activity
US5451569A (en) 1994-04-19 1995-09-19 Hong Kong University Of Science And Technology R & D Corporation Limited Pulmonary drug delivery system
US5869451A (en) 1995-06-07 1999-02-09 Glaxo Group Limited Peptides and compounds that bind to a receptor
US6251864B1 (en) * 1995-06-07 2001-06-26 Glaxo Group Limited Peptides and compounds that bind to a receptor
US5654276A (en) * 1995-06-07 1997-08-05 Affymax Technologies N.V. Peptides and compounds that bind to the IL-5 receptor
US5683983A (en) * 1995-06-07 1997-11-04 Glaxo Group Limited Peptides and compounds that bind to the IL-5 receptor
WO1996040189A1 (en) 1995-06-07 1996-12-19 Glaxo Group Limited Peptides and compounds that bind to a receptor
EP0886648B8 (en) 1995-06-07 2004-03-03 Ortho Pharmaceutical Corporation Compounds and peptides that bind to the erythropoietin receptor
US5767078A (en) * 1995-06-07 1998-06-16 Johnson; Dana L. Agonist peptide dimers
US5668110A (en) * 1995-06-07 1997-09-16 Affymax Technologies N.V. Peptides and compounds that bind to the IL-5 receptor
ES2303338T3 (es) 1995-06-07 2008-08-01 Glaxo Group Limited Peptidos y compuestos que se unen a un receptor de trombopoyetina.
US5677280A (en) * 1995-06-07 1997-10-14 Glaxo Group Limited Peptides and compounds that bind to the IL-5 receptor
US5672662A (en) * 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
US6346390B1 (en) * 1996-03-08 2002-02-12 Receptron, Inc. Receptor derived peptides involved in modulation of response to ligand binding
US6103879A (en) * 1996-06-21 2000-08-15 Axys Pharmaceuticals, Inc. Bivalent molecules that form an activating complex with an erythropoietin receptor
DE69736780T2 (de) * 1996-08-02 2007-09-06 Ortho-Mcneil Pharmaceutical, Inc. Polypeptide mit einzelnem kovalent gebundenen n-terminalen wasserlöslichen polymer
US5932546A (en) * 1996-10-04 1999-08-03 Glaxo Wellcome Inc. Peptides and compounds that bind to the thrombopoietin receptor
KR100497423B1 (ko) * 1996-10-25 2005-07-07 지.디. 썰 엘엘씨 다기능 키메라 조혈 수용체 아고니스트
US6221608B1 (en) * 1997-01-22 2001-04-24 Ortho Pharmaceutical Corporation Methods for identifying erythropoietin receptor binding protein
JP4304757B2 (ja) 1998-04-24 2009-07-29 株式会社デンソー Ａｂｓアクチュエータ
PL202799B1 (pl) 1998-08-06 2009-07-31 Mountain View Pharmaceuticals Sposób izolowania urykazy w postaci tetramerycznej oraz wyizolowana tetrameryczna urykaza
CA2338665C (en) * 1998-08-06 2011-01-18 Mountain View Pharmaceuticals, Inc. Peg-urate oxidase conjugates and use thereof
US6783965B1 (en) 2000-02-10 2004-08-31 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
EP1008355A1 (en) 1998-12-08 2000-06-14 Debio Recherche Pharmaceutique S.A. Method for identifying or analyzing polymer linkage sites on macromolecules using amino acid report binding
HK1043801A1 (zh) 1998-08-28 2002-09-27 格莱风科学公司 精确长度的聚酰胺链、其制备方法和其与蛋白质的缀合物
DK1783222T3 (da) 1998-10-23 2012-07-09 Kirin Amgen Inc Dimere trombopoietiske peptidomimetika, der binder til MPL-receptor og har trombopoietisk aktivitet
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6498155B1 (en) * 1998-11-17 2002-12-24 Smithkline Beecham Corporation Methods of treating thrombocytopenia
CZ299516B6 (cs) * 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
JO2291B1 (en) * 1999-07-02 2005-09-12 اف . هوفمان لاروش ايه جي Erythropoietin derivatives
AUPQ873300A0 (en) * 2000-07-12 2000-08-03 Medvet Science Pty. Ltd. A binding motif of a receptor (2)
AU771460B2 (en) * 1999-09-24 2004-03-25 Smithkline Beecham Corporation Thrombopoietin mimetics
AU7445900A (en) * 1999-09-27 2001-04-30 Chugai Seiyaku Kabushiki Kaisha Novel hemopoietin receptor protein, nr12
US6703480B1 (en) * 1999-11-24 2004-03-09 Palani Balu Peptide dimers as agonists of the erythropoientin (EPO) receptor, and associated methods of synthesis and use
US6858630B2 (en) * 1999-12-06 2005-02-22 Smithkline Beecham Corporation Naphthimidazole derivatives and their use as thrombopoietin mimetics
AU8149901A (en) * 2000-03-21 2001-10-03 Wisconsin Alummi Res Foundatio Methods and reagents for regulation of cellular responses in biological systems
US6777387B2 (en) * 2000-03-31 2004-08-17 Enzon Pharmaceuticals, Inc. Terminally-branched polymeric linkers containing extension moieties and polymeric conjugates containing the same
CZ304855B6 (cs) * 2000-05-15 2014-12-10 F. Hoffmann-La Roche Ag Kapalná farmaceutická kompozice obsahující pegylovaný lidský erythropoetin, způsob její přípravy, léčivo pro léčení chorob korelujících s anemií při chronickém renálním selhání a zařízení s jejím obsahem
IL153079A0 (en) 2000-05-26 2003-06-24 Ortho Mcneil Pharm Inc Neuroprotective peptides
YU7503A (sh) * 2000-08-02 2006-03-03 Ortho-Mcneil Pharmaceutical Inc. Anti-virusna i anti-tumorna hemoterapija poboljšana davanjem eritropoetina
CN1458846A (zh) * 2000-09-08 2003-11-26 格莱风治疗公司 促红细胞生成性合成蛋白
AU2002233230B2 (en) * 2000-12-20 2007-02-01 F. Hoffmann-La Roche Ag Erythropoietin conjugates
US6531121B2 (en) * 2000-12-29 2003-03-11 The Kenneth S. Warren Institute, Inc. Protection and enhancement of erythropoietin-responsive cells, tissues and organs
US7767643B2 (en) * 2000-12-29 2010-08-03 The Kenneth S. Warren Institute, Inc. Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
DK1362053T3 (da) 2001-02-20 2008-03-10 Enzon Inc Terminalt forgrenede polymere linkere og polymere konjugater indeholdende disse
FR2823220B1 (fr) * 2001-04-04 2003-12-12 Genodyssee Nouveaux polynucleotides et polypeptides de l'erythropoietine (epo)
US20020169128A1 (en) * 2001-04-09 2002-11-14 Geroge Sigounas Erythropoietin ameliorates chemotherapy-induced toxicity in vivo
ATE414711T1 (de) 2001-06-28 2008-12-15 Mountain View Pharmaceuticals Polymerstabilisierte proteinasen
US6784154B2 (en) * 2001-11-01 2004-08-31 University Of Utah Research Foundation Method of use of erythropoietin to treat ischemic acute renal failure
US7122189B2 (en) 2002-08-13 2006-10-17 Enzon, Inc. Releasable polymeric conjugates based on aliphatic biodegradable linkers
US7087229B2 (en) 2003-05-30 2006-08-08 Enzon Pharmaceuticals, Inc. Releasable polymeric conjugates based on aliphatic biodegradable linkers
US20050176627A1 (en) * 2002-09-09 2005-08-11 Anthony Cerami Long acting erythropoietins that maintain tissue protective activity of endogenous erythropoietin
US20040062748A1 (en) 2002-09-30 2004-04-01 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US8129330B2 (en) * 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US7396913B2 (en) * 2002-10-14 2008-07-08 Abbott Laboratories Erythropoietin receptor binding antibodies
AU2003291719A1 (en) * 2002-11-06 2004-06-03 Schering Corporation Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
WO2004060299A2 (en) 2002-12-26 2004-07-22 Mountain View Pharmaceuticals, Inc. Polymer conjugates of interferon-beta with enhanced biological potency
CA2511815A1 (en) 2002-12-26 2004-07-22 Mountain View Pharmaceuticals, Inc. Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity
EP1625156B1 (en) 2003-05-12 2012-09-19 Affymax, Inc. Peptides that bind to the erythropoietin receptor
AU2004238870B8 (en) 2003-05-12 2010-04-15 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
EP1626983B8 (en) 2003-05-12 2010-12-22 Affymax, Inc. Novel poly (ethylene glycol) modified erythropoietin agonists and uses thereof
JP2007500218A (ja) 2003-05-12 2007-01-11 アフィーマックス・インコーポレイテッド ポリ（エチレングリコール）修飾ペプチド系化合物の新規スペーサー部分
US7550433B2 (en) * 2005-06-03 2009-06-23 Affymax, Inc. Erythropoietin receptor peptide formulations and uses

Also Published As

Publication number Publication date
BRPI0613233A2 (pt) 2010-12-28
UA92497C2 (ru) 2010-11-10
SG162747A1 (en) 2010-07-29
MA29557B1 (fr) 2008-06-02
CR9570A (es) 2008-05-05
KR20080021115A (ko) 2008-03-06
US7550433B2 (en) 2009-06-23
CA2609401A1 (en) 2006-12-14
AU2006255081B2 (en) 2012-03-29
US20090136442A1 (en) 2009-05-28
IL187354A0 (en) 2008-04-13
GEP20135981B (en) 2013-12-10
JP2008542399A (ja) 2008-11-27
AU2006255081A1 (en) 2006-12-14
US20070104704A1 (en) 2007-05-10
US7906485B2 (en) 2011-03-15
EP1917023A4 (en) 2010-03-24
MX2007015303A (es) 2008-03-05
KR20120119921A (ko) 2012-10-31
NZ563433A (en) 2009-12-24
KR101262312B1 (ko) 2013-05-14
EP1917023A2 (en) 2008-05-07
JP2013173763A (ja) 2013-09-05
NO20076634L (no) 2008-02-29
WO2006133144A8 (en) 2008-04-17
EA200702656A1 (ru) 2008-12-30
CN101553242A (zh) 2009-10-07
WO2006133144A2 (en) 2006-12-14
EA014528B1 (ru) 2010-12-30

Similar Documents

Publication Publication Date Title
ZA200711020B (en) Erythropoietin receptor peptide formulations and uses
IL192104A0 (en) Stable protein formulations
GB2424581B (en) Formulations
PL1940240T3 (pl) Kompozycje izolatu białka i ich zastosowania
EP1988922A4 (en) PROTEIN FORMULATIONS
ZA200707654B (en) Formulations
IL185308A0 (en) Replikin peptides and uses thereof
EP1909584A4 (en) PRENYLFLAVONOID FORMULATIONS
GB0508863D0 (en) Peptide
EP1951693A4 (en) SOLID FORMULATIONS
EP1953227A4 (en) BINDER OF LIPOPOLYSACCHARIDE OR LIPID A, AND NEW PEPTIDE
EP2195002A4 (en) ERYTHROPOETIN RECEPTOR PEPTIDE FORMULATIONS AND USES
GB0517293D0 (en) Vectors and uses thereof
GB0526019D0 (en) Peptides
PL1928232T3 (pl) Stała formulacja
GB0516527D0 (en) Peptides
HK1116072A (en) Erythropoietin receptor peptide formulations and uses
ZA200707282B (en) Improved cosmetic composition
GB0516571D0 (en) Novel polypeptides and uses thereof
GB0517813D0 (en) Peptides and uses thereof
SI1962886T1 (sl) Stabilne proteinske formulacije
GB0509835D0 (en) Peptide
GB0516303D0 (en) Peptide
GB0522917D0 (en) Formulations
GB0526322D0 (en) Formulations